EyePoint：三期临床设计构建更具价值的“药效持久性”故事 (NASDAQ:EYPT)
· seekingalpha.com
EyePoint 即将迎来关键的二元催化剂：DURAVYU 治疗湿性老年性黄斑变性（wet AMD）的 LUGANO 三期临床数据预计将于 2026 年 8 月公布。点击此处阅读更多关于 EYPT 股票的信息。
My optimism about EyePoint ( EYPT ) rests on more than the possibility that DURAVYU will reduce injection frequency in retinal diseases. More importantly, EyePo...